Revenue
2019
2020
2021
2022
2023
2024
2025
aTYR PHARMA INC (ATYR)
Price$0.4973Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $190,000 | $235,000 | $353,000 | $10.4M | $0 | $10.5M | $422,000 | — | — | — | — | — | — |
| Research & development | $60.2M | $54.4M | $42.3M | $42.8M | $23.3M | $17.3M | $14.0M | $20.4M | $30.1M | $42.8M | $34.5M | $16.8M | $13.8M |
| Operating expenses | $77.8M | $68.1M | $55.3M | $56.8M | $34.0M | $26.4M | $23.4M | $32.8M | $47.1M | $57.9M | $47.6M | $23.6M | $19.5M |
| Operating income | −$77.6M | −$67.9M | −$54.9M | −$46.4M | −$34.0M | −$15.9M | −$23.0M | −$32.8M | −$47.1M | −$57.9M | −$47.6M | −$23.6M | −$19.5M |
| Operating margin | −40,856.32% | −28,899.57% | −15,557.79% | −446.79% | — | −152.19% | −5,445.02% | — | — | — | — | — | — |
| EBITDA | −$77.0M | −$67.2M | −$54.3M | −$46.2M | −$33.5M | −$15.3M | −$22.3M | −$32.1M | −$46.4M | −$57.0M | −$46.7M | −$22.7M | −$18.8M |
| EBITDA margin | −40,506.84% | −28,598.30% | −15,390.08% | −444.56% | — | −146.74% | −5,294.55% | — | — | — | — | — | — |
| Net income | −$74.1M | −$64.0M | −$50.4M | −$45.3M | −$33.8M | −$16.2M | −$16.2M | −$34.5M | −$48.2M | −$57.9M | −$48.0M | −$24.4M | −$20.0M |
| Net profit margin | −39,009.47% | −27,243.83% | −14,274.50% | −436.53% | — | −155.18% | −3,844.55% | — | — | — | — | — | — |
| Basic EPSper basic share | -$0.80 | -$0.86 | -$0.94 | -$1.60 | -$1.77 | -$1.77 | -$7.03 | -$16.11 | -$26.13 | -$34.16 | -$42.42 | -$415.66 | -$397.46 |
| Diluted EPSper diluted share | -$0.80 | -$0.86 | -$0.94 | -$1.60 | -$1.77 | -$1.77 | -$7.03 | -$16.11 | -$26.13 | -$34.16 | -$42.42 | -$415.66 | -$397.46 |
Owners
Reported shareholders
8.68%of listed shares
FEDERATED HERMES, INC.8.51M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
FEDERATED HERMES, INC. | 8.68%8.51M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.88%3.81M shares |
Kalehua Capital Management LLC | 3.65%3.58M shares |
GSA CAPITAL PARTNERS LLP | 3.52%3.45M shares |
AQR CAPITAL MANAGEMENT LLC | 2.66%2.61M shares |
FMR LLC | 2.52%2.47M shares |
BlackRock, Inc. | 1.86%1.83M shares |
JANE STREET GROUP, LLC | 1.75%1.72M shares |
UBS Group AG | 1.56%1.53M shares |
MORGAN STANLEY | 1.37%1.34M shares |
TWO SIGMA INVESTMENTS, LP | 1.27%1.25M shares |
CITADEL ADVISORS LLC | 1.27%1.24M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.20%1.18M shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.76%747.04K shares |
MILLENNIUM MANAGEMENT LLC | 0.67%656.05K shares |
GOLDMAN SACHS GROUP INC | 0.65%641.21K shares |
VANGUARD FIDUCIARY TRUST CO | 0.59%576.13K shares |
STATE STREET CORP | 0.50%494.95K shares |
MARSHALL WACE, LLP | 0.38%368.12K shares |
XTX Topco Ltd | 0.23%226.68K shares |
Percentages use 98.09M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 27, 2026Form 4 | SCHIMMEL PAULDirector | BuyCommon Stock · indirect | 100.0K | $0.50 | $50.0K | 779.1K |
| Feb 4, 2026Form 4 | Shukla SanjayPresident and CEO | SellCommon Stock | 3.7K | $0.98 | $3.7K | 153.6K |
| Feb 4, 2026Form 4 | Broadfoot Jill MarieChief Financial Officer | SellCommon Stock | 1.6K | $0.98 | $1.5K | 37.3K |
| Feb 4, 2026Form 4 | DENYES NANCYGeneral Counsel | SellCommon Stock | 1.1K | $0.98 | $1.1K | 33.1K |
| Oct 9, 2025Form 4 | SCHIMMEL PAULDirector | BuyCommon Stock · indirect | 318.0K | $0.94 | $298.9K | 1.41M |
Community posts
aTyr outlines a new Phase 3 sarcoidosis study after FDA discussions
aTyr Pharma ($ATYR) said it had aligned with the FDA on the design of a Phase 3 study of efzofitimod in pulmonary sarcoidosis patients with restrictive lung disease. The planned trial would enroll 372 patients and compare treatment with pla ...
